Clinical trials: Tic Disorders
Tourette Syndrome
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance…
- Trial name
- ARTISTS (NCT03567291)
- Testing
- TEV-50717
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 228 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Brain Injuries, Wounds and Injuries
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study
Trauma is the leading cause of death and disability in children in the United States. The long-term goal of this project is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely…
- Conditions
- Brain Injuries, Wounds and Injuries, Hemorrhage
- Trial name
- TIC-TOC (NCT02840097)
- Testing
- Tranexamic Acid
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Daniel Nishijima, MD, MAS
Tourette Syndrome
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
- Trial name
- NCT03530293
- Testing
- Valbenazine
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 81 people
- Sponsor
- Neurocrine Biosciences
Tourette Syndrome
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
This is a two-part, randomized, multi-center, blinded study in adolescents with Tourette's Disorder. There will be an up to 21-day screening period in which subject eligibility will be determined.
- Trial name
- NCT01904773
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418339
- Testing
- Aripiprazole
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment.
- Trial name
- NCT02679079
- Testing
- NBI-98854
- Where
- 44 sites in United States
- Volunteers
- 98 people
- Sponsor
- Neurocrine Biosciences
Tourette Syndrome, Tic Disorders
Median Nerve Stimulation Pilot
Results from the University of Nottingham suggested that rhythmic median nerve stimulation (MNS) improves tic symptoms in Tourette syndrome (TS).
- Conditions
- Tourette Syndrome, Tic Disorders, Tic Disorder, Chronic Motor or Vocal
- Trial name
- MNS (NCT04731714)
- Testing
- Rhythmic median nerve stimulation, Arrhythmic median nerve stimulation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Tourette Syndrome
Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tics are the core symptom of Tourette syndrome. These are repetitive, sudden, semi-voluntary movements or sounds. In some children, these tics can be especially bad and require treatment, however, options are limited.
- Trial name
- TICS (NCT02356003)
- Testing
- Low frequency repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Calgary
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder, Tic Disorder
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine efficacy and safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727700
- Testing
- Aripiprazole
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 133 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome, Chronic Tic Disorder
Median Nerve Stimulation for Tourette Syndrome and Chronic Tic Disorder
Tourette syndrome (TS) and chronic tic disorder (CTD) are neurodevelopmental disorders that impact approximately 1% of 5-18 year olds worldwide.
- Trial name
- NeSTS (NCT05269953)
- Testing
- Active stimulation
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Tourette Syndrome
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching…
- Trial name
- D1AMOND (NCT04007991)
- Testing
- Ecopipam
- Where
- 70 sites in United States, Canada and 3 more
- Volunteers
- 153 people
- Sponsor
- Emalex Biosciences Inc.
Tourette Syndrome
A Randomized, Placebo-controlled, Tourette Syndrome Study.
Previous studies using topiramate in Tourette subjects have shown that with the use of this medication subjects report that their tics get better.
- Trial name
- NCT00206323
- Testing
- Topiramate (drug)
- Volunteers
- 29 people
- Sponsor
- Baylor College of Medicine
Tourette's Disorder, Tic Disorder
Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727713
- Testing
- Aripiprazole
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria.
- Trial name
- NCT00558467
- Testing
- pramipexole immediate release (IR)
- Where
- 16 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Tic Disorders, Tourette Syndrome
Comparison of Keppra and Clonidine in the Treatment of Tics
The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine.
- Trial name
- NCT00370838
- Testing
- Levetiracetam, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Harvey S. Singer
Tourette Syndrome
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.
- Trial name
- ARTISTS1 (NCT03452943)
- Testing
- TEV-50717
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 119 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tourette Syndrome
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
A joint NIH -Tourette Syndrome Association Conference has emphasized the critical need for the testing and development of new pharmacotherapy for tic suppression in Tourette syndrome (TS).
- Trial name
- NCT01018056
- Testing
- D-serine, Riluzole
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Johns Hopkins University
Tourette's Disorder
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01416441
- Testing
- Aripiprazole
- Where
- 80 sites in United States, Bulgaria and 8 more
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Disorder, Chronic Tic Disorder
Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo
Expert reviews and practice parameter papers recommend behavior therapy as a first-line intervention for youth with chronic tic disorders (CTDs) with mild-to-moderate tic severity.
- Trial name
- DCS+HRT (NCT02582515)
- Testing
- D-cycloserine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles